| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/28/2011 | EP2368575A2 Dry formulation for transcutaneous immunization |
| 09/28/2011 | EP2368558A1 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates |
| 09/28/2011 | EP2367564A1 Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| 09/28/2011 | EP2367543A2 5-ht2a and 5-ht2b receptor antagonist for treating stenosis of the spinal canal |
| 09/28/2011 | EP2367449A1 Composition comprising isoflavones |
| 09/28/2011 | EP2133335B1 Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor |
| 09/28/2011 | EP2040734B1 Antisecretory protein for use in the treatment of compartment syndrome |
| 09/28/2011 | EP1962838B1 Farnesoid x receptor agonists |
| 09/28/2011 | EP1806132B1 Stat3 phosphorylation inhibitor and notch1 expression inhibitor |
| 09/28/2011 | EP1463531B1 Methods for inhibiting ocular processes |
| 09/28/2011 | EP1426054B1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 09/28/2011 | EP1424330B1 Activator for peroxisome proliferator-responsive receptor delta |
| 09/28/2011 | EP1420800B1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity |
| 09/28/2011 | EP1322307B1 Methods for treating cell proliferative disorders and viral infections |
| 09/28/2011 | EP1237891B1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/28/2011 | EP1144613B1 Methods for making proteins containing free cysteine residues |
| 09/28/2011 | CN1994343B Pharmaceutical composition having functions in activating blood and invigorating qi and preparation process thereof |
| 09/28/2011 | CN1915981B 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 09/28/2011 | CN102203085A Processes for the preparation of crystalline forms of sunitinib malate |
| 09/28/2011 | CN102202662A Agent for treatment of diabetes |
| 09/28/2011 | CN102199618A Method for constructing mutant recombinant plasmid of PPARalpha gene V227A |
| 09/28/2011 | CN102199197A Polypeptides with function of self-assembled potassium channel and its application |
| 09/28/2011 | CN102198082A Micelle loaded with Tacrolimus or pharmaceutical salts thereof, lyophilized preparation as well as preparation methods and applications |
| 09/28/2011 | CN101829145B Elk horn active site and preparation method and application thereof |
| 09/28/2011 | CN101584741B Radix sophorae tonkinensis total flavonoids, flavone salt and preparation method thereof |
| 09/28/2011 | CN101570528B Glycyrrhizin derivatives and preparation and use thereof |
| 09/27/2011 | US8026346 Tribonectins |
| 09/27/2011 | US8026273 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient |
| 09/27/2011 | US8026213 Methods for treating muscle diseases and disorders |
| 09/27/2011 | US8025898 Enhanced drug delivery in transdermal systems |
| 09/27/2011 | US8025883 Antagonists and methods for inhibiting angiogenesis |
| 09/27/2011 | CA2506476C Method of treatment of myocardial infarction |
| 09/27/2011 | CA2473409C Phenoxy-piperidines for the treatment of diseases such as schizophrenia and depression |
| 09/27/2011 | CA2462337C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2457410C Compounds effecting glucokinase |
| 09/27/2011 | CA2447276C Non-human animal model of oligodendrocyte developmental disorder |
| 09/27/2011 | CA2440630C Metalloproteinase inhibitors |
| 09/27/2011 | CA2440042C Carboxamide derivatives as therapeutic agents |
| 09/27/2011 | CA2372553C Attenuated microorganisms for the treatment of infection |
| 09/27/2011 | CA2370206C Pharmaceutical compositions for inhibition of cytokine production and secretion |
| 09/27/2011 | CA2351015C Novel system for regulating transgene expression |
| 09/27/2011 | CA2258728C Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| 09/22/2011 | WO2011115183A1 Novel monocyclic pyrimidine derivative |
| 09/22/2011 | WO2011115173A1 Monomaleate of benzothiazine compound |
| 09/22/2011 | WO2011115106A1 Pharmaceutical for pseudo-exercise therapy |
| 09/22/2011 | WO2011115066A1 Crystal of diamine derivative and method of producing same |
| 09/22/2011 | WO2011115065A1 Cyclopropanecarboxylic acid derivative |
| 09/22/2011 | WO2011115064A1 Cycloalkyl-substituted imidazole derivative |
| 09/22/2011 | WO2011115062A1 Adjuvant having anti-tumor effect |
| 09/22/2011 | WO2011115061A1 Hyaluronic acid production promoter |
| 09/22/2011 | WO2011113190A1 Pharmaceutical composition for treating aids and preparation method thereof |
| 09/22/2011 | WO2011056599A3 Caged ceramide-1-phosphate derivatives |
| 09/22/2011 | US20110230637 Modified human thymic stromal lymphopoietin |
| 09/22/2011 | US20110230550 Compounds, compositions and methods |
| 09/22/2011 | US20110230541 Process for the preparation of rotigotine |
| 09/22/2011 | US20110230519 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 09/22/2011 | US20110230485 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors |
| 09/22/2011 | US20110230467 4,6-diaminonicotinamide compound |
| 09/22/2011 | US20110230446 Cathepsin cysteine protease inhibitors |
| 09/22/2011 | US20110230409 GLP-I Agonist And Cardiovascular Complications |
| 09/22/2011 | US20110230408 Human growth hormone aqueous formulation |
| 09/22/2011 | US20110229579 Support Having Nanostructured Titanium Dioxide Film And Uses Thereof |
| 09/22/2011 | US20110229577 Biologically active silicic acid |
| 09/22/2011 | US20110229558 Agent for treating myelofibrosis |
| 09/22/2011 | US20110229497 Modulating the Alternative Complement Pathway |
| 09/22/2011 | US20110229466 Vascular endothelial growth factor 2 |
| 09/22/2011 | US20110229440 Differentiation of Human Embryonic and Induced Pluripotent Stem Cells |
| 09/22/2011 | US20110229432 Thermosensitive composition preventing tissue adhesion and preparation method thereof |
| 09/22/2011 | US20110229416 Amphiphilic macromolecules for solubilizing nanocrystals |
| 09/22/2011 | US20110229414 Contrast Agents For Detecting Protease Activity By Means Of Hyperpolarization And For Stratifying Patients |
| 09/22/2011 | US20110229409 Linkable lewis x analogs |
| 09/22/2011 | CA2793523A1 Cyclopropanecarboxylic acid derivative |
| 09/22/2011 | CA2793413A1 Crystal form of edoxaban tosylate monohydrate and method of producing same |
| 09/22/2011 | CA2791505A1 Cycloalkyl-substituted imidazole derivative |
| 09/21/2011 | EP2366774A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366773A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366772A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366771A2 PUFA polyketide synthase systems and uses thereof |
| 09/21/2011 | EP2366713A2 Polypeptide variants with altered effector function |
| 09/21/2011 | EP2366706A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 09/21/2011 | EP2366701A1 Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof |
| 09/21/2011 | EP2366699A1 8-substituted isoquinoline derivative and use thereof |
| 09/21/2011 | EP2366395A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis |
| 09/21/2011 | EP2366389A1 Severe sepsis preventive therapeutic agent |
| 09/21/2011 | EP2351742A8 Indazole derivative |
| 09/21/2011 | EP1674106B1 Dietetic composition |
| 09/21/2011 | EP1531873B1 Agent delivery particle |
| 09/21/2011 | EP1505963B9 Hepatitis c virus inhibitors |
| 09/21/2011 | EP1492811B1 Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin |
| 09/21/2011 | EP1436298B1 Himbacine analogues as thrombin receptor antagonists |
| 09/21/2011 | EP1334178B1 Slo2 and slo4, novel potassium channel proteins from human brain |
| 09/21/2011 | EP1003728B1 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate |
| 09/21/2011 | EP0725791B1 Recombinant p53 adenovirus methods and compositions |
| 09/21/2011 | CN1894278B Akt activity specifically inhibiting polypeptide |
| 09/21/2011 | CN1864434B Wireless microphone communication system |
| 09/21/2011 | CN102197028A Piperidine derivative, piperazine derivative and agent for treatment of disease involving central nervous system disorders |
| 09/21/2011 | CN102197017A Cyclohexylamine derivative containing phenyl group, and therapeutic agent for diseases accompanied by central nervous system disorders |
| 09/21/2011 | CN102196819A Composition for local anesthesia |
| 09/21/2011 | CN102196810A Pharmaceutical composition improved in absorption through intestinal tract |
| 09/21/2011 | CN102190721A Long-acting growth hormone |